Skip to content
Menu

Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Avi Kapoor 6 hours ago

MarketsTrading IdeasPre-Market OutlookMoversNews

U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 100 points on Tuesday.

Shares of Red Cat Holdings, Inc. (NASDAQ:RCAT) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results and withdrew its FY26 revenue target.

Red Cat reported quarterly losses of 26 cents per share, which missed the consensus estimate of 21 cents, per Benzinga Pro data. Quarterly revenue came in at $11.77 million, which missed the Street estimate of $39.51 million by 70.21%.

Red Cat shares dipped 25.8% to $2.62 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

  • Solid Biosciences Inc. (NASDAQ:SLDB) declined 7.4% to $6.00 in pre-market trading after dropping 5% on Monday.
  • Sasol Ltd (NYSE:SSL) fell 6.8% to $12.97 in pre-market trading after reports suggesting that municipal-level government talks between the ANC and DA parties may have destabilizing consequences for the Government of National Unity.
  • Kyverna Therapeutics Inc (NASDAQ:KYTX) declined 5.5% to $4.50 in pre-market trading after dipping around 6% on Monday.
  • Braskem S.A. (NYSE:BAK) declined 5.4% to $0.92 in pre-market trading after dipping 14% on Monday.
  • Omeros Corp (NASDAQ:OMER) fell 5.3% to $15.79 in pre-market trading after the company reported mixed quarterly financial results.
  • Corsair Gaming Inc (NASDAQ:CRSR) declined 5.2% to $10.66 in pre-market trading following around 5% drop on Monday.
  • Deutsche Bank AG (NYSE:DB) fell 5.1% to $34.00 in pre-market trading after reports suggesting that the bank dodged compliance rules, processed more payments to Epstein than originally known, and planned a Russia expansion based on more business with Kremlin-aligned companies and individuals.
  • JetBlue Airways Corp (NASDAQ:JBLU) declined 4.6% to $3.55 in pre-market trading.
  • Aclaris Therapeutics Inc (NASDAQ:ACRS) dipped 4.3% to $3.45 in pre-market trading. Aclaris Therapeutics CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study.   

Photo via Shutterstock

Read at benzinga.com